With nearly 60% of all of last year’s FDA new drug approvals coming from companies with a footprint in New Jersey, the Garden State’s robust life sciences community has once again played a prominent role in delivering novel life-changing therapies and cures to Patients around the world. We look forward to even more innovation in the year to come, as this week’s Weekender highlights the many new FDA approvals, research, clinical trials and partnerships already underway.
Congratulations to BIO — the world’s largest biotechnology trade association — for changing its name to theBiotechnology Innovation Organization to better reflect the remarkable progress and groundbreaking innovations that its members are achieving in healing, fueling and feeding the world.
New Jersey was just named one of the top five innovative states in the U.S. The Bloomberg U.S. Innovation Index scored each of the 50 states on a 0-100 scale across six equally weighted metrics: R&D intensity; productivity; high-tech density; concentration of science, technology, engineering and mathematics (STEM) employment; science and engineering degree holders and patent activity.
The FDA approval of the first ever extended release chewable tablet by Monmouth Junction-based Tris Pharma, Inc. is just one example of the wide breadth of innovation taking place in the Garden State. Congratulations!
BioNJ Member Matinas BioPharma announced that the FDA has designated the company’s lead drug candidate MAT2203 as a Qualified Infectious Disease Product with Fast Track status for the treatment of aspergillus and it has filed an Investigational New Drug Application for its lead antibacterial development candidate, MAT2501.
BioNJ Member Amicus Therapeutics announced that its Investigational New Drug Application is now effective which allows the company to begin site initiation and enrollment of a Phase 1/2 study of ATB200 in patients with Pompe disease.
Bridgewater-based Intrexon Corporation announced that it has entered into a research collaboration agreement with BioNJ Member Johnson & Johnson Innovation to discover and develop ActoBiotics® therapies directed against selected targets to treat type 2 diabetes, obesity and/or metabolic disorders related to energy dysregulation.
Come celebrate New Jersey’s innovation at BioNJ’s 23rd Annual Gateway Gala, Dinner Meeting & Innovation Celebration scheduled for February 4, 2016. The inspirational evening will include a Keynote by theHonorable Patrick Kennedy, the presentation of the ninth annual Dr. Sol J. Barer Award to Clive Meanwell, M.D., Ph.D., Founder and CEO of The Medicines Company and the much anticipated Innovator Awardshonoring companies with a footprint in New Jersey that received an FDA approval in 2015 to be presented by the precious 7-year old Max Schill. Register now. The Early Bird deadline is next Friday, January 15.
Click here to read this week’s Weekender.